Biomarin Pharmaceutical Inc at Goldman Sachs Global Healthcare Conference Transcript
Thank you, everyone, for joining us. I'm Salveen Richter, one of the biotechnology analysts at Goldman Sachs, and we're pleased to have BioMarin with us today. We have Hank Fuchs, who is the President of Worldwide Research & Development and Chief Medical Officer as well. So Hank, with that, I think you wanted to make some opening remarks?
Sure. Wow, that's loud. Better. BioMarin, just to remind people, a 21-year-old company. Unusual for a 21-year-old company and 7 products on the market in over 70 different countries and delivering each of these products, it's not just the first product -- it's not just the best product for the indication, the first product for the indication and the only product for the indication. So we've been a company known for making breakthrough advances in patients with very difficult-to-treat diseases and have very fundamental and profound impacts in those patients
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
